<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795248</url>
  </required_header>
  <id_info>
    <org_study_id>GDM-TREAT</org_study_id>
    <secondary_id>2012-001371-37</secondary_id>
    <nct_id>NCT01795248</nct_id>
  </id_info>
  <brief_title>The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes</brief_title>
  <official_title>The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tina Vilsboll</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well-known that women with previous gestational diabetes mellitus are in risk of
      developing type 2 diabetes later in life; approximately half of the women develop overt type
      2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the
      effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous
      gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glucose tolerance</measure>
    <time_frame>from baseline to 52 wks, 53 wks, 260 wks, and 261 wks</time_frame>
    <description>Changes in glucose is measured by area under the curve for the plasma glucose excursion following a 4-hour 75 g oral glucose tolerance test (OGTT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deterioration in glycaemic status</measure>
    <time_frame>from baseline to 52 wks, 53, wks, 260 wks, and 261 wks</time_frame>
    <description>Percentage of subjects in each treatment arm with normal glucose tolerance (NGT) at inclusion who develop impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) or type 2 diabetes; or with IFG or IGT who develop combined IFG/IGT; or with combined IFG/IGT who develop type 2 diabetes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in glycated hemoglobin</measure>
    <time_frame>From baseline to 52 wks and 260 wks</time_frame>
    <description>Changes in glycated hemoglobin (HbA1c). From normoglycaemic to prediabetic or type 2 diabetic and from prediabetic to type 2 diabetic or normoglycaemic.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in anthropometric measurements</measure>
    <time_frame>from baseline to 52 and 260 wks</time_frame>
    <description>Changes in body mass index (BMI)(kg/m2), absolute body weight (kg), and waist:hip ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in beta cell secretory responses</measure>
    <time_frame>from baseline to 52, 53, 260, and 261 wks</time_frame>
    <description>changes in area under the curve during OGTT and isoglycemic intravenous glucose infusion (IIGI), the homeostatic model assessment (HOMA) and pro-insulin ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in insulin sensitivity</measure>
    <time_frame>from baseline to 52, 53, 260, and 261 wks</time_frame>
    <description>assessed by HOMA-IR and Matsuda insulin sensitivity index</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in incretin hormone secretion</measure>
    <time_frame>baseline to 52, 53, 260, and 261 wks</time_frame>
    <description>measured as fasting plasma concentrations and plasma responses of GLP-1, GLP2, and GIP and plasma glucagon during OGTT</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in incretin effect</measure>
    <time_frame>baseline to 52, 53, 260, and 261 wks</time_frame>
    <description>insulin and c-peptide responses after OGTT vs. IIGI</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in cardio-metabolic risk measures</measure>
    <time_frame>baseline to 52 and 260 wks</time_frame>
    <description>pro-collagen 3, GGT, Intra-hepatic fat, whole body and visceral fat mass/fat-free mass, circulating lipids and cardiovascular biomarkers (highly sensitive c-reactive protein (hs-CRP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), tumor necrosis factor-alpha (TNF-alpha), adiponectin and plasminogen activator inhibior-1 (PAI-1))</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in gut microbiota</measure>
    <time_frame>baseline to 52 and 260 wks</time_frame>
    <description>optional to the main protocol</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in subjective appetite</measure>
    <time_frame>baseline to 52, 53, 260, and 261 wks</time_frame>
    <description>visual analogue scale (VAS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events (Safety and tolerability)</measure>
    <time_frame>baseline to 52 and 260 wks</time_frame>
    <description>as assessed by validated questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>Baseline to 52 and 260 wks</time_frame>
    <description>Assessed by validated questionnaires (SF-36)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of alcohol consumption</measure>
    <time_frame>baseline to 52 and 260 wks</time_frame>
    <description>By validated questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of microalbuminuria</measure>
    <time_frame>baseline to 52 to 260 wks</time_frame>
    <description>Predicitve value of biomarkers for detection of microalbuminuria</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of blindedness of participants and investigators</measure>
    <time_frame>baseline to 52 wks</time_frame>
    <description>questionnaire and the end of the blinded trial</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in bonemarkers</measure>
    <time_frame>baseline to 52 and 260 wks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.8 mg liraglutide, subcutaneous, once-daily for five years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, subcutaneous, once-daily for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control without previous GDM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>1.8 mg liraglutide</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
    <other_name>NN2211</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Liraglutide without the GLP-1 analogue</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for women with previous GDM:

          -  Informed oral and written consent

          -  Previous diagnosis of GDM according to current Danish guidelines (mainly PG
             concentrationa t 120 min after 75 g OGTT â‰¥ 9.0 mM) during pregnancy within the last 5
             years

          -  Age &gt;18 years

          -  25 kg/m2 &lt; BMI &lt; 45 kg/m2

          -  NGT, IFG and or IGT

          -  Safe contraception and negative pregnancy test

        Exclusion Criteria for women with previous GDM:

          -  Patients with diabetes

          -  HbA1c â‰¥6.5%

          -  Patients with previous pancreatitis or previous neoplasia

          -  Pregnant or breast feeding women

          -  Anaemia (haemoglobin &lt;7 mM)

          -  Women planning to become pregnant within the next 5 years

          -  Women using other contraception than intrauterine device (IUD) or oral contraceptives.
             Women who do not use safe contraception will be offered application of an IUD.

          -  Women treated with statins, corticosteroids or other hormone therapy (except estrogens
             and gestagens)

          -  Ongoing abuse of alcohol or narcotics

          -  Impaired hepatic function (liver transaminases &gt;3 times upper normal limit)

          -  Impaired renal function (se-creatinine &gt;120 Î¼M and/or albuminuria)

          -  Uncontrolled hypertension (systolic blood pressure &gt;180 mmHg, diastolic blood pressure
             &gt;100 mmHg)

          -  Any condition that the investigator feels would interfere with trial participation

          -  Receiving any investigational drug within the last 3 months

        Inclusion criteria for women without previous GDM:

          -  Informed oral and written consent

          -  Age &gt;18 years

          -  25 kg/m2 &lt; BMI &lt; 45 kg/m2

          -  NGT

          -  Safe contraception and negative pregnancy test

          -  Pregnancy within the last ten years without GDM

        Exclusion Criteria for women without previous GDM :

          -  Pregnant or breast feeding women

          -  Anaemia (haemoglobin &lt;7 mM)

        Inclusion Criteria for women without previous GDM and without NAFLD:

          -  Informed oral and written consent

          -  Age &gt;18 years

          -  25 kg/m2 &lt; BMI &lt; 45 kg/m2

          -  NGT

          -  At least one pregnancy witin the last ten years without GDM

        Exclusion Criteria for women without previous GDM and without NAFLD:

          -  Pregnant or breast feeding women

          -  Anaemia (haemoglobin &lt;7 mM)

          -  Steatosis as assessed by ultrasound scanning

          -  Recieving any investigational drug within the last 3 months

          -  Any condition that the investigator feels would interfere with the trial participation

        Inclusion Criteria for women with biopsi-verified NAFLD:

          -  Informed oral and written consent

          -  Women with known NAFLD or NASH

          -  Age &gt;18 years

          -  25 kg/m2 &lt; BMI &lt; 45 kg/m2

          -  NGT

          -  At least one prior pregnancy

        Exclusion Criteria for women with biopsi-verified NAFLD:

          -  women with established cirrhosis

          -  Pregnant or breast feedning women

          -  Anaemia (haemoglobin &lt;7 mM)

          -  Women treated with statins, corticosteroids or other hormone therapy ( except
             oestrogens and gestagens)

          -  Ongoing abuse of alcohol or narcotics

          -  Impaired renal function (se-creatinine &gt; 120 Î¼M and/or albuminuria)

          -  Uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg, diastolic blood presure
             &gt; 100 mmHg)

          -  Any condition that the investigator feels would interfere with trial participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina VilsbÃ¸ll, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Gentofte</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Signe Foghsgaard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Gentofte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Diabetes Research</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://gentoftehospital.dk</url>
    <description>Main website for the University Hospital Gentofte</description>
  </link>
  <reference>
    <citation>Porte D Jr. Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction. Ann N Y Acad Sci. 1999 Nov 18;892:73-83. Review.</citation>
    <PMID>10842653</PMID>
  </reference>
  <reference>
    <citation>VilsbÃ¸ll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004 Mar;47(3):357-366. doi: 10.1007/s00125-004-1342-6. Epub 2004 Feb 13. Review.</citation>
    <PMID>14968296</PMID>
  </reference>
  <reference>
    <citation>VilsbÃ¸ll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. Dan Med Bull. 2004 Nov;51(4):364-70.</citation>
    <PMID>16009062</PMID>
  </reference>
  <reference>
    <citation>Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. Review.</citation>
    <PMID>17928588</PMID>
  </reference>
  <reference>
    <citation>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602.</citation>
    <PMID>9742976</PMID>
  </reference>
  <reference>
    <citation>Damm P, Vestergaard H, KÃ¼hl C, Pedersen O. Impaired insulin-stimulated nonoxidative glucose metabolism in glucose-tolerant women with previous gestational diabetes. Am J Obstet Gynecol. 1996 Feb;174(2):722-9.</citation>
    <PMID>8623813</PMID>
  </reference>
  <reference>
    <citation>Jensen DM, MÃ¸lsted-Pedersen L, Beck-Nielsen H, Westergaard JG, Ovesen P, Damm P. Screening for gestational diabetes mellitus by a model based on risk indicators: a prospective study. Am J Obstet Gynecol. 2003 Nov;189(5):1383-8.</citation>
    <PMID>14634573</PMID>
  </reference>
  <reference>
    <citation>Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998 Aug;21 Suppl 2:B161-7.</citation>
    <PMID>9704245</PMID>
  </reference>
  <reference>
    <citation>Lauenborg J, Hansen T, Jensen DM, Vestergaard H, MÃ¸lsted-Pedersen L, Hornnes P, Locht H, Pedersen O, Damm P. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care. 2004 May;27(5):1194-9.</citation>
    <PMID>15111544</PMID>
  </reference>
  <reference>
    <citation>Xiang AH, Kjos SL, Takayanagi M, Trigo E, Buchanan TA. Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus. Diabetes. 2010 Oct;59(10):2625-30. doi: 10.2337/db10-0521. Epub 2010 Aug 3.</citation>
    <PMID>20682697</PMID>
  </reference>
  <reference>
    <citation>Hanna FW, Peters JR. Screening for gestational diabetes; past, present and future. Diabet Med. 2002 May;19(5):351-8. Review.</citation>
    <PMID>12027921</PMID>
  </reference>
  <reference>
    <citation>Bian X, Gao P, Xiong X, Xu H, Qian M, Liu S. Risk factors for development of diabetes mellitus in women with a history of gestational diabetes mellitus. Chin Med J (Engl). 2000 Aug;113(8):759-62.</citation>
    <PMID>11776065</PMID>
  </reference>
  <reference>
    <citation>Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998 Aug;19(4):491-503. Review.</citation>
    <PMID>9715377</PMID>
  </reference>
  <reference>
    <citation>Forbes S, Taylor-Robinson SD, Patel N, Allan P, Walker BR, Johnston DG. Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia. 2011 Mar;54(3):641-7. doi: 10.1007/s00125-010-2009-0. Epub 2010 Dec 12.</citation>
    <PMID>21153530</PMID>
  </reference>
  <reference>
    <citation>Astrup A, RÃ¶ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Erratum in: Lancet. 2010 Mar 20;375(9719):984.</citation>
    <PMID>19853906</PMID>
  </reference>
  <reference>
    <citation>Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, RÃ¶ssner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012 Jun;36(6):890. Int J Obes (Lond). 2013 Feb;37(2):322.</citation>
    <PMID>21844879</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48.</citation>
    <PMID>10702749</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20.</citation>
    <PMID>9449682</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Tina Vilsboll</investigator_full_name>
    <investigator_title>Dr. Tina VilsbÃ¸ll, DMSc</investigator_title>
  </responsible_party>
  <keyword>gestational diabetes mellitus</keyword>
  <keyword>incretin</keyword>
  <keyword>glucose homeostasis</keyword>
  <keyword>GLP-1</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>liraglutide</keyword>
  <keyword>Victoza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

